Orano Med Enters Next Phase of Collaboration with Roche

Orano Med, a subsidiary of the Orano group, is advancing its collaboration with Roche to the next phase, focusing on developing a novel cancer treatment called "two-step pretargeted radioimmunotherapy" (PRIT). This approach targets tumors with an antibody that captures lead-212 to attack cancer cells. Orano Med will manufacture 212Pb in France and the US. The collaboration aims to develop therapies for cancers with limited treatment options, with a phase 1 clinical trial expected in 2026.